Centro de Pesquisas Clinicas
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | LGI1 Autoimmune Encephalitis; NMDAR Autoimmune Encephalitis | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05503264 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04586023 | |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04544449 | |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-14 | NCT07351058 | |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-14 | NCT07351045 | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05271409 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Phase 1 | 2026-08-13 | NCT07667322 |